anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
200 hundred Subjects will be treated with a dose escalation regimen to achieve a target blood pressure. Subjects with mild hypertension at baseline will be started with losartan 50 mgs and those with severe hypertension will be started with losartan H 100/25. After 6 weeks they will titrated if goal blood pressure not achieved. For Mild hypertensive group this will be with losartan H 100/25 and for severe hypertensive group this will by addition of amlodipine 5 mg to regime. Subjects with mild hypertension and diabetes at baseline will be started with losartan H 50/12.5 mg and those with severe hypertension with diabetes will be started with losartan H 100/25. After 6 weeks they will be titrated if goal blood pressure not achieved. For Mild hypertensive-diabetic group this will be with Resilo H 100/25 and for severe hypertensive group this will by addition of amlodipine 5 mg to regime.

Target Blood Pressure is systolic \< 140 mmhg and diastolic \< 90 mmHg if age \< 60 years and systolic \< 150 mmHg and diastolic \< 90 mmHg if age \>60 years.
A surgical instrument for cutting and stapling patient tissue is disclosed. The surgical instrument comprises an end effector including a staple cartridge and staples, a firing element configured to move through the staple cartridge to cut the patient tissue and eject the staples from the staple cartridge during a staple firing stroke, an elongate shaft extending from the end effector, and a handle extending from the elongate shaft. The handle comprises a motor configured to output a rotary motion. The firing element is operably responsive to the rotary motion. The firing element is further configured to be driven at different speeds during the staple firing stroke. The handle further comprises a display. The display is configured to display the different speeds of the firing element during the staple firing stroke as a graphical representation.
NEW MATERIAL:Compounds represented by formula I [R1 is morpholino, imidazolyl, formula II (R2 is H or 2-hydroxyethyl; R3 is H, 2-hydroxyethyl, amino, acyl, etc.)]. EXAMPLE:1 Amino-4-(pyridinyl)phthalazine. USE:A remedy for heart failure having a circulation-improvement effect without progression of myocardiopathy. PREPARATION:For example, an o-halotoluene of formula II (X is halogen) is reacted with 4-cyanopyridine to obtain a ketone compound of formula IV and the resultant ketone compound is subsequently hydrolyzed to obtain a carboxylic acid derivative. The obtained carboxylic acid derivative is then reacted with hydrazine hydrate to obtain a compound of formula V and the resultant compound is reacted with phosphorus oxychloride to obtain a 1- chlorophthalazine compound. Phenol is reacted thereon to obtain a 1- phenoxyphthalazine derivative to obtain its 1-phenoxyphthalazine derivative and the resultant derivative is treated with ammonium acetate, thus providing the objective 1-amino-4-(4-pyridinyl) phthalazine.
PROBLEM TO BE SOLVED: To enable casting of a porcelain baking alloy for casting for dentistry with a high m.p. by mixing a specified pts.wt. of one or more kinds of metal powder with specified value of m.p. and oxide forming free energy and a thermal conductivity of at least that of Fe into a mixture of α-hemihydrate gypsum and quartz and/or cristabalite. SOLUTION: A mixture of α-hemihydrate gypsum as a binder and quartz and/or cristobalit as a refractory is prepd. 100 pts.wt. of this mixture are mixed with 0.5-5 pts.wt. one or more kinds of metal powder with a m.p. of at least 1,400 deg.C, an oxide forming free energy value at 1,000 deg.C of at least -90.000 cal/ g.mol O2 and a thermal conductivity of at least that of Fe. In a precise casting system for dentistry, it is an essential condition to compound fine silica particles to obtain a smooth and glossy surface condition and it is possible by mixing this metal powder with a high thermal conductivity to improve heat dissipation ability of a mold and further, to prevent surface roughening from being generated.
PROBLEM TO BE SOLVED: To obtain a powdery skin lotion for bodies, having a refreshing feeling and a dry touch of use without stickiness and white by blending a remarkable amount of a lower alcohol with a specific powder and a liquid oil in combination. SOLUTION: This powdery skin lotion for bodies is obtained by blending a lower alcohol with a porous and/or a water absorbing powders and a liquid oil. The amount of the blended lower alcohol is 50.0-92.0wt.%, preferably >=60.0wt.% and that of the blended porous and/or water absorbing powders is 5.0-30.0wt.%, preferably 10.0-20.0wt.%. The amount of the blended liquid oil is 2.0-20.0wt.%, preferably 4.0-10.0wt.%. Methanol, ethanol, propanol, etc., are preferred as the liquid oil and the ethanol is especially preferred. Corn starch, potato starch and silicic acid anhydride are preferred as the powders. Cetyl octanoate and jojoba oil are preferred as the liquid oil. A perfume in an amount of about 0.5-30.0wt.% may be blended in the system.
FIELD: crystal growing. SUBSTANCE: high eutectic purity (at least 98%) crystal modification B with melting point 73 C, preferably 73-75 C, and NH oscillations in IR spectra 3200-3300 cm -1 , in contrast to modification A, is not disposed for crystal growth when used as fungicidal substance. Substance is stable on large-scale storage preserving its original good capability of being suspended and dispersed. Crystal modification B is prepared by crystallization either in organic solvent at temperature above 26 C or from melt with initial temperature 72-74 C. Fungicidal composition contains crystal modification B with melting point above 73 C in fungicidal amount in combination with a relevant carrier. EFFECT: increased purity and storage stability. 11 cl, 2 dwg, 6 tbl, 9 ex
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to medicinal preparations improving cerebral circulation. Composition for improving cerebral circulation comprises vinpocetine and piracetam as active substances being the composition is incorporated into solid gelatin capsule. As special additions the composition comprises lactose and calcium stearate in the following ratio of components, g per 1 capsule: vinpocetine, 0.0045-0.0055; piracetam, 0.3600-0.4400; lactose, 0.0990-0.1210; calcium stearate, 0045-0.0055. Invention provides creating the capsulated form of preparation eliciting the combined effect of vinpocetine and piracetam. EFFECT: enhanced effectiveness of composition, valuable medicinal properties, expanded assortment of medicinal agents for improving cerebral circulation. 2 tbl
Patients will receive ADI-PEG 20 on Day -7 of Cycle 1 and Days 1, 8, and 15 of each of three 21-day cycles, and ifosfamide per dose escalation/de-escalation schedule on days 1 through 5 of each cycle. Mesna will be given on days 1 through 5 with ifosfamide as supportive care. Patients will also receive radiotherapy (XRT) starting on Week 4.
<P>PROBLEM TO BE SOLVED: To provide a program for selecting a medicine matching to resistant bacteria, a storage medium with the program stored, and a system for selecting a medicine matching to resistant bacteria which can conduct the so-called "tailor-made" inspection, and can suppress the spread of resistant bacteria by the administration of a small quantity of antibiotic.  <P>SOLUTION: The program has a database corresponding to medicines in which the genetic types of resistant bacteria, and medicines which are effective to genetic types and including at least an antibiotic are enumerated, a genetic type entry means, a medicine-retrieving means, a screening means, and a result output means. The genetic type entry means inputs the genetic type of bacterium of inspection object, and then notifies the medicine-retrieving means of it. The medicine-retrieving means retrieves a medicine, matching the notified genetic type from the database corresponding to the medicines, and the result output means outputs the retrieved medicine in a prescribed form. The screening means performs screening for a medicine matching the genetic type.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
INTRODUCTION: This study aimed to evaluate the role of intravenous lidocaine as a adjuvant anesthetics in patients undergoing gynecological surgery.
EVIDENCE ACQUISITION: We conducted a meta-analysis of randomized controlled trials (RCTs) from PubMed/Medline, Embase and clinic trails.gov involving the use of intravenous lidocaine in gynecological surgery. We used a more comprehensive search strategy to adequately screen for randomized controlled trials involving intravenous lidocaine infusion in gynecological surgery. First outcomes were postoperative pain scores. And secondary outcomes included 24 h postoperative opioids consumption, time to first flatus, and incidence of postoperative nausea and vomiting.
EVIDENCE SYNTHESIS: A total of 6 RCTs comprising 375 patients were included in the meta-analysis. There were statistically significant between postoperative pain scores. The consumption of opioids and anesthetics during surgery and 24 hours after surgery was statistically significant when compared with the control group. Postoperative pain scores were similar at 2, 4, 6, 8, 10, 12, 24, 48 hours between groups. No statistical differences were found in postoperative complications including nausea, vomiting and restoration of the intestinal function.
CONCLUSIONS: Our results indicated that the current literature supports the perioperative use of intravenous lidocaine as part of multimodal analgesia and beneficial to patients in early postoperative analgesia, reduced opioid consumption.
The invention discloses a Chinese medicinal herb composition for curing biliary tract ascariasis. The Chinese medicinal herb composition is characterized by comprising the following components in proportion: 25 to 35 parts of dark plum fruit, 5 to 15 parts of manchurian wildginger, 15 to 25 parts of dried ginger, 25 to 35 parts of Chinese angelica, 5 to 15 parts of cassia twig, 15 to 25 parts of amur corktree bark, 15 to 25 parts of golden thread, 15 to 25 parts of ginseng, 5 to 15 parts of zanthoxylum pipertum DC, 15 to 25 parts of stone-like omphalia, 15 to 25 parts of Chinaberry seed and 5 to 15 parts of fennel fruit. The Chinese medicinal herb composition is prepared by adding 1,000 parts of water; boiling the mixture in a casserole; decocting the mixture over slow fire for three times, and uniformly mixing the obtained supernate; filtering and bottling the supernate; and sterilizing the supernate at the high temperature for later use. The Chinese medicinal herb composition takes the dark plum fruit as a monarch, takes the manchurian wildginger and the dried ginger as ministers, takes the Chinese angelica, the cassia twig, the amur corktree bark and the golden thread as assistants, and takes the ginseng, the zanthoxylum pipertum DC, the stone-like omphalia and the fennel fruit as guides. The Chinese medicinal herb composition can effectively cure the acute biliary tract ascariasis. Based on the therapeutic principles of clearing heat and removing retention, and warming the stomach and relieving colic caused by ascaris, the Chinese medicinal herb composition has the advantages of obvious treatment effect, convenient taking, and low treatment cost and has the effect of treating both principal and secondary aspects of diseases.
After obtaining written and verbal approval from the families of the patients included in the placebo control group by signing the Informed Volunteer Consent Form, the patients were filled out the Patient Introduction Form, Patient Monitoring Form and Medication Monitoring Form by the nurses. According to the oil application protocol, the massage with almond oil was performed by the researcher in 6 consecutive steps by stroking the patient's back and chest, effleurage, re-effleurage, deep stroking of the back and stroking the back surface.
Smartwatches (SW) are wearable devices that support daily life and monitor an individual's health and activity status. This information is utilized to promote behavior modification, which could help prevent chronic diseases and manage the health of older adults. Despite being interested in SWs, older adults tend to decrease their SW usage as they age. Therefore, understanding the acceptance of SWs among older individuals can facilitate individual health management through digital health technology. This study investigated the factors associated with the acceptance of SWs among older adults in Japan and the variations in the factors by sex. This study utilized data from the 2022 Itabashi Longitudinal Study on Aging, an ongoing cohort study conducted by the Tokyo Metropolitan Institute for Geriatrics and Gerontology. We included 899 eligible individuals aged ≥65 years. Participants were classified into three groups: possessing SW (possessor group), not possessing SW but interested in possession in the future (interest group), and not interested in possession in the future (non-interest group) using a self-administered questionnaire. The level of SW acceptance was operationally defined as follows: low (non-interest group), medium (interest group), and high (possessor group). Further, we evaluated the association of acceptance and purchase intentions of SWs with sociodemographic variables, technology literacy, and health variables. Among the participants, 4.2% possessed SWs, with no significant sex difference (men, 4.2%; women, 4.3%). Among men, age < 75 years, obesity, diabetes, and dyslipidemia were significantly associated with SW acceptance level. Contrastingly, among women, age < 75 years, living alone, higher household income, and a high score for new device use in the technology literacy category were significantly associated with SW acceptance level. Health-related factors were associated with SW acceptance in men, while technology literacy and sociodemographic factors were associated with SW acceptance in women. Our findings may inform the development of sex-specific interventions and policies for increasing SW utilization among older adults in Japan.
Ultrasound-guided deposition of 40mls of 2mg/ kg levobupivacaine into the deep serratus anterior plane space, in the mid axillary line, at the level of the 4th/5th rib. Insertion of a continuous local anaesthetic infusion catheter(Portex™) and continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
All participants received VX-147 at a dosage of 15 mg once daily (qd) for 2 weeks and VX-147 at a dosage of 45 mg qd for 11 weeks. Part A was enrolled in 2 cohorts: Cohort 1 and Cohort 2. Cohort 1 included participants with urine protein to creatinine ratio (UPCR) approximately greater than or equal to (≥) 3 g/g (± 10%) and less than (\<) 10 g/g and estimated glomerular filtration rate (eGFR) approximately ≥30 mL/min/1.73 m2 (± 10%). Cohort 2 included participants with UPCR approximately ≥0.8 g/g (± 10%) and \<2.7 g/g and eGFR approximately ≥30 mL/min/1.73 m2.
A composition and method for affixing a dental appliance to the teeth characterized by effecting a layer of catalyst that will effect polymerization of a bonding resin on the surface of the teeth to which the dental appliance is to be affixed, after the surface has been cleaned and dried so as to effect a good bond; effecting a layer of the catalyst on the base of at least a portion of the dental appliance that is to be bonded to the teeth after the base has been cleaned and dried so as to effect a good bond; positioning the base of the portion of the dental appliance adjacent the teeth after resin has been applied intermediate the two layers of catalyst on the base and on the surface of the tooth. After a predetermined cure time, the remainder of the dental appliance is affixed in place. The bonding resin is selected from the group consisting of epoxy, per se or capped with hydrolysis-resistant moiety; urethane; cyano-acrylate; methacrylate; vinyl ester; and acrylate. Appropriate catalyst such as benzoyl peroxide and initiator are preferably employed for effecting polymerization. Also, critical viscosity of the bonding resin in the range of 25,000-40,000 centipoises, as measured with a Brookfield Niscometer at 50° C., is employed, with filler if necessary, to obtain the desired wettability and prevent "creep" during gellation. Also disclosed are preferred constituents and steps in the method, including the indirect bonding method.
This solution is for intravenous use only after admixture or dilution. Do not inject until made approximately isotonic by addition of appropriate solute.

Following suitable admixture of prescribed drugs, the dosage is usually dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. See directions accompanying drugs.

The dosage and administration of Sterile Water for Injection USP is dependent upon the recommended dosage and administration of the solute used. Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient.

Some additives may be incompatible. Consult with pharmacist. When performing admixture or dilution, use aseptic techniques. Mix thoroughly. Do not store.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Technologies are generally described for controlling food intake. Example devices/systems described herein may include an image sensor, a dietary information identifier, a dietary management unit, and an image display unit. The image sensor may capture an image of a dish or a menu. The dietary information identifier may identify the dish or menu from the image and provide meal dietary information based on the identified dish or menu. The dietary management unit may store personal dietary information and determine combined dietary information based on the personal dietary information and the meal dietary information. The image display unit may process the captured image based on the combined dietary information in such a manner that a part of the captured image is hidden on an image display unit or a part of color or text information of the captured image is changed on the image display unit.
The invention relates to pentaerythritol-based composite lipid and a preparation method thereof, belonging to the field of a biomedical material. The defects of poor stability and low packaging rate of the existing liposome prepared with lipid can be overcome. The chemical structure formula of the composite lipid is shown as below. The pentaerythritol-based composite lipid is prepared via introduction of fat chain, siloxane, carboxyl, phenyl ring and the like on a pentaerythritol framework via chemical reaction. The liposome prepared with the lipid has a uniform size, the surface of the liposome has a silicate network structure and has good stability, medical leakage cannot be caused easily, and the packaging rate is 96.6-99.0 percent. Moreover, the process of the method is simple, and the clinical application and industrial production can be facilitated.
The prognostic implication of cognitive frailty assessment in patients undergoing left ventricular assist device (LVAD) implantation remains unclear. We conducted a systematic review to evaluate assessment strategies and their significance for patients undergoing LVAD implantation. A comprehensive search of PubMed, Embase, and the Cumulative Index to Nursing and Allied Health Literature from inception until September 2022 and a review of meeting proceedings were performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Studies that investigated the prognostic value of cognitive frailty or any related cognition-based assessment in patients undergoing LVAD implantation were included. Study characteristics, patient demographics, and type of cognitive assessment were extracted. Primary outcomes included length of stay, readmissions, and all-cause mortality. Of 664 records retrieved, 12 (4 prospective, 8 retrospective) involving 16 737 subjects (mean age, 56.9 years; 78.3% men) met inclusion criteria; 67% of studies used the Montreal Cognitive Assessment to assess cognitive frailty. Outcomes reported were highly variable, with 42% reporting readmission, 33% reporting LOS, and 83% reporting mortality data; only two studies provided data on all three. Cognitive frailty was associated with prolonged length of stay in 75% of studies reporting this outcome. Only 40% and 60% of studies that reported readmissions and mortality outcomes, respectively, suggested a predictive association. Pre-LVAD cognitive frailty is likely associated with worse outcomes postimplant. However, the heterogenous reporting of outcomes data and lack of consistent definitions in the literature limit its prognostic value. Additional research on markers for cognitive frailty and improved standards of reporting may allow for future analyses and enhance preoperative risk assessment and patient care. Geriatr Gerontol Int 2024; 24: 204-210.
BACKGROUND: Laparoscopic cholecystectomy (LC) is the standard of care for symptomatic gall stone disease. A good scoring system is necessary to standardize the reporting. Our aim was to develop and validate an objective scoring system, the Surgical Cholecystectomy Score (SCS) to grade the difficulty of LC.
METHODS: The study was conducted in a single surgical unit at a tertiary care hospital in two phases from January 2017 to April 2021. Retrospective data was analysed and the difficulty of each procedure was graded according to the modified Nassar's scoring system. Significant preoperative and intraoperative data obtained was given a weightage score. In phase II, these scores were validated on a prospective cohort. Each procedure was classified either as easy, moderately difficult or difficult.
STATISTICAL ANALYSIS: A univariate analysis was performed on the data followed by a multivariate regression analysis. Bidirectional stepwise selection was done to select the most significant variables. The Beta /Schneeweiss scoring system was used to generate a rounded risk score.
RESULTS: Data of 800 patients was retrieved and graded. 10 intraoperative parameters were found to be significant. Each variable was assigned a rounded risk score. The final SCS range for intraoperative parameters was 0-15. The scoring system was validated on a cohort of 249 LC. In the final scoring, cut off SCS of > 8 was found to correlate with difficult procedures. Score of < 2 was equivalent to easy LC. A score between 2 and 8 indicated moderate difficulty. The area under ROC curve was 0.98 and 0.92 for the intraoperative score indicating that the score was an excellent measure of the difficulty level of LCs.
CONCLUSION: The scoring system developed in this study has shown an excellent correlation with the difficulty of LC. It needs to be validated in different cohorts and across multiple centers further.
PURPOSE:To prepare a drink and food, etc. useful for enriching the physical strength and vigor, recorvering the sexual function and promoting the health, by dipping fruits of a yew in an alcohol, vinegar, etc. to extract various components contained therein. CONSTITUTION:Fruits of a yew in any optional form, e.g. the natural form or compressed, pulverized, frozen or dried form, are dipped in an alcohol, SAKE, low-class distilled spirit or whisky, acetic acid, citric acid or vinegar or a mixture thereof to extract various components contained therein. the resultant extract solution may be directly or if desired processed into a tablet, granule, powder, health food, health drink or chemical, etc.